Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;44(8):1564-1576.
doi: 10.1002/cbin.11359. Epub 2020 Apr 18.

New insights into small-cell lung cancer development and therapy

Yuwen Wang  1 , Songyun Zou  1 , Zhuyun Zhao  1 , Po Liu  1 , Changneng Ke  1 , Shi Xu  1   2
Affiliations
Review

New insights into small-cell lung cancer development and therapy

Yuwen Wang et al. Cell Biol Int. 2020 Aug.

Abstract

Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases; however, it is characterized by easy relapse and low survival rate, leading to one of the most intractable diseases in clinical practice. Despite decades of basic and clinical research, little progress has been made in the management of SCLC. The current standard first-line regimens of SCLC still remain to be cisplatin or carboplatin combined with etoposide, and the adverse events of chemotherapy are by no means negligible. Besides, the immunotherapy on SCLC is still in an early stage and novel studies are urgently needed. In this review, we describe SCLC development and current therapy, aiming at providing useful advices on basic research and clinical strategy.

Keywords: lung morphogenesis; small-cell lung cancer; therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

Figures

Figure 1
Figure 1
The role of PNECs in lung development. NCAM1, neural cell adhesion molecule; NEB, neuroepithelial body; PNEC, pulmonary neuroendocrine cell
See this image and copyright information in PMC

References

    1. Allison Stewart, C. , Tong, P. , Cardnell, R. J. , Sen, T. , Li, L. , Gay, C. M. , … Byers, L. A. (2017). Dynamic variations in epithelial‐to‐mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget, 8(17), 28575–28587. 10.18632/oncotarget.15338 - DOI - PMC - PubMed
    1. Altan, M. , & Chiang, A. C. (2015). Management of small cell lung cancer: Progress and updates. Cancer Journal, 21(5), 425–433. 10.1097/PPO.0000000000000148 - DOI - PubMed
    1. Antonia, S. J. , Lopez‐Martin, J. A. , Bendell, J. , Ott, P. A. , Taylor, M. , Eder, J. P. , … Calvo, E. (2016). Nivolumab alone and nivolumab plus ipilimumab in recurrent small‐cell lung cancer (CheckMate 032): a multicentre, open‐label, phase 1/2 trial. The Lancet Oncology, 17(7), 883–895. 10.1016/S1470-2045(16)30098-5 - DOI - PubMed
    1. Ardizzoni, A. , Hansen, H. , Dombernowsky, P. , Gamucci, T. , Kaplan, S. , Postmus, P. , … Verweij, J. (1997). Topotecan, a new active drug in the second‐line treatment of small‐cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Journal of Clinical Oncology, 15(5), 2090–2096. 10.1200/JCO.1997.15.5.2090 - DOI - PubMed
    1. Auperin, A. , Arriagada, R. , Pignon, J. P. , Le Pechoux, C. , Gregor, A. , Stephens, R. J. , … Prophylactic Cranial Irradiation Overview Collaborative Group . (1999). Prophylactic cranial irradiation for patients with small‐cell lung cancer in complete remission. New England Journal of Medicine, 341(7), 476–484. 10.1056/NEJM199908123410703 - DOI - PubMed

MeSH terms